• 1
    Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 15419.
  • 2
    Catassi C, Fanciulli G, D'Appello AR, et al. Antiendomysium versus antigliadin antibodies in screening the general population for coeliac disease. Scand J Gastroenterol 2000; 35: 7326.
  • 3
    Ho GT, Mowat A, Potts L, et al. Efficacy and complications of adalimumab treatment for medically-refractory Crohn's disease: analysis of nationwide experience in Scotland (2004–2008). Aliment Pharmacol Ther 2009; 29: 52734.
  • 4
    Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398405.
  • 5
    Targan SR, Hanauer SB, Van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 102935.
  • 6
    Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999; 117: 7619.
  • 7
    Rutgeerts P, Van AG, Vermeire S. Review article: infliximab therapy for inflammatory bowel disease–seven years on. Aliment Pharmacol Ther 2006; 23: 45163.
  • 8
    Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350: 87685.
  • 9
    Sewell JL, Mahadevan U. Infliximab and surgical complications: truth or perception? Gastroenterology 2009; 136: 3545.
  • 10
    Holubar SD, Cima RR, Pemberton JH. Does infliximab increase complications after surgery for inflammatory bowel disease? F1000 Med Rep 2009; 1: 10.
  • 11
    Cornillie F, Shealy D, D'Haens G, et al. Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Aliment Pharmacol Ther 2001; 15: 46373.
  • 12
    Appau KA, Fazio VW, Shen B, et al. Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn's patients. J Gastrointest Surg 2008; 12: 173844.
  • 13
    Canedo J, Lee SH, Pinto R, Murad-Regadas S, Rosen L, Wexner SD. Surgical resection in Crohn's disease: is immunosuppressive medication associated with higher postoperative infection rates? Colorectal Dis 2011; 13: 12948.
  • 14
    Kasparek MS, Bruckmeier A, Beigel F, et al. Infliximab does not affect postoperative complication rates in Crohn's patients undergoing abdominal surgery. Inflamm Bowel Dis 2012; 18: 120713.
  • 15
    Marchal L, D'Haens G, Van AG, et al. The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study. Aliment Pharmacol Ther 2004; 19: 74954.
  • 16
    El-Hussuna A, Andersen J, Bisgaard T, et al. Biologic treatment or immunomodulation is not associated with postoperative anastomotic complications in abdominal surgery for Crohn's disease. Scand J Gastroenterol 2012; 47: 6628.
  • 17
    Kunitake H, Hodin R, Shellito PC, Sands BE, Korzenik J, Bordeianou L. Perioperative treatment with infliximab in patients with Crohn's disease and ulcerative colitis is not associated with an increased rate of postoperative complications. J Gastrointest Surg 2008; 12: 17306.
  • 18
    Regadas FS, Pinto RA, Murad-Regadas SM, et al. Short-term outcome of infliximab and other medications on patients with inflammatory bowel disease undergoing ileostomy reversal. Colorectal Dis 2011; 13: 55560.
  • 19
    Waterman M, Xu W, Dinani A, et al. Preoperative biological therapy and short-term outcomes of abdominal surgery in patients with inflammatory bowel disease. Gut 2012; doi: 10.1136/gutjnl-2011-301495 [Epub ahead of print].
  • 20
    Nasir BS, Dozois EJ, Cima RR, et al. Perioperative anti-tumor necrosis factor therapy does not increase the rate of early postoperative complications in Crohn's disease. J Gastrointest Surg 2010; 14: 185965.
  • 21
    Colombel JF, Loftus EV, Tremaine WJ, et al. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol 2004; 99: 87883.
    Direct Link:
  • 22
    Brzezinski A, Armstrong L, Real GAD, et al. Infliximab does not increase the risk of complications in the perioperative period in patients with Crohn's disease. Gastroenterology 2002; 122: A-617.
  • 23
    Pedersen CB, Gotzsche H, Moller JO, Mortensen PB. The Danish Civil Registration System. A cohort of eight million persons. Dan Med Bull 2006; 53: 4419.
  • 24
    Andersen TF, Madsen M, Jorgensen J, Mellemkjoer L, Olsen JH. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull 1999; 46: 2638.
  • 25
    Arendrup MC, Bruun B, Christensen JJ, et al. National surveillance of fungemia in Denmark (2004–2009). J Clin Microbiol 2011; 49: 32534.
  • 26
    Laupland KB, Schonheyder HC, Kennedy KJ, et al. Rationale for and protocol of a multi-national population-based bacteremia surveillance collaborative. BMC Res Notes 2009; 2: 146.
  • 27
    Trick WE, Zagorski BM, Tokars JI, et al. Computer algorithms to detect bloodstream infections. Emerg Infect Dis 2004; 10: 161220.
  • 28
    Weinstein MP, Reller LB, Murphy JR, Lichtenstein KA. The clinical significance of positive blood cultures: a comprehensive analysis of 500 episodes of bacteremia and fungemia in adults. I. Laboratory and epidemiologic observations. Rev Infect Dis 1983; 5: 3553.
  • 29
    Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 37383.
  • 30
    Fonager K, Sorensen HT, Rasmussen SN, Moller Petersen J, Vyberg M. Assessment of the diagnoses of Crohn's disease and ulcerative colitis in a Danish hospital information system. Scand J Gastroenterol 1996; 31: 1549.
  • 31
    Mller C, Kehlet H, Utzon J, Ottesen B. Hysterectomy in Denmark. An analysis of postoperative hospitalisation, morbidity and readmission 2002. Dan Med Bull 2002; 49: 3537.
  • 32
    Utzon J, Olsen PS, Bay-Nielsen M, et al. Evaluation of surgical interventions in Denmark. Ugeskr Laeger 2001; 163: 56624.
  • 33
    Ottesen M. Validity of the registration and reporting of vaginal prolapse surgery. Ugeskr Laeger 2009; 171: 4048.
  • 34
    Harboe KM, Anthonsen K, Bardram L. Validation of data and indicators in the Danish Cholecystectomy Database. Int J Qual Health Care 2009; 21: 1608.
  • 35
    Norgard BM, Nielsen J, Qvist N, Gradel KO, de Muckadell OB, Kjeldsen J. Pre-operative use of anti-TNF-alpha agents and the risk of post-operative complications in patients with ulcerative colitis - a nationwide cohort study. Aliment Pharmacol Ther 2012; 35: 13019.